Evidence for field cancerization of the prostate - PubMed (original) (raw)
Review
Evidence for field cancerization of the prostate
Larisa Nonn et al. Prostate. 2009.
Abstract
Background: Field cancerization, which is not yet well-characterized in the prostate, occurs when large areas of an organ or tissue surface are affected by a carcinogenic insult, resulting in the development of multi-focal independent premalignant foci and molecular lesions that precede histological change.
Methods: Herein, we review the cumulative body of evidence concerning field effects in the prostate and critically evaluate the methods available for the identification and validation of field effect biomarkers. Validated biomarkers for field effects have an important role to play as surrogate endpoint biomarkers in Phase II prevention trials and as clinical predictors of cancer in men with negative biopsies.
Results: Thus far, field effects have been identified involving nuclear morphometric changes, gene expression, protein expression, gene promoter methylation, DNA damage and angiogenesis. In addition to comparing cancer-adjacent benign tissue to more distant areas or to "supernormal" tissue from cancer-free organs, investigators can use a nested case-control design for negative biopsies that offers a number of unique advantages.
Conclusions: True carcinogenic field effects should be distinguished from secondary responses of the microenvironment to a developing tumor, although the latter may still lead to useful clinical prediction tools. Prostate 69: 1470-1479, 2009. (c) 2009 Wiley-Liss, Inc.
Figures
Fig. 1
Nested case–control study design for epidemiological validation of field effect tissue biomarkers.
Similar articles
- Prostate field cancerization and exosomes: Association between CD9, early growth response 1 and fatty acid synthase.
Amirrad F, Pytak PA, Sadeghiani-Pelar N, Nguyen JPT, Cauble EL, Jones AC, Bisoffi M. Amirrad F, et al. Int J Oncol. 2020 Apr;56(4):957-968. doi: 10.3892/ijo.2020.4980. Epub 2020 Feb 10. Int J Oncol. 2020. PMID: 32319557 - Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies.
Yang B, Etheridge T, McCormick J, Schultz A, Khemees TA, Damaschke N, Leverson G, Woo K, Sonn GA, Klein EA, Fumo M, Huang W, Jarrard DF. Yang B, et al. Clin Epigenetics. 2019 Nov 28;11(1):168. doi: 10.1186/s13148-019-0771-5. Clin Epigenetics. 2019. PMID: 31779677 Free PMC article. - Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection.
Jarrard WE, Schultz A, Etheridge T, Damodaran S, Allen GO, Jarrard D, Yang B. Jarrard WE, et al. PLoS One. 2019 Jun 24;14(6):e0218950. doi: 10.1371/journal.pone.0218950. eCollection 2019. PLoS One. 2019. PMID: 31233548 Free PMC article. - Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. Cucchiara V, et al. Eur Urol. 2018 Apr;73(4):572-582. doi: 10.1016/j.eururo.2017.10.036. Epub 2017 Nov 10. Eur Urol. 2018. PMID: 29129398 Review.
Cited by
- Markers of field cancerization: proposed clinical applications in prostate biopsies.
Trujillo KA, Jones AC, Griffith JK, Bisoffi M. Trujillo KA, et al. Prostate Cancer. 2012;2012:302894. doi: 10.1155/2012/302894. Epub 2012 May 14. Prostate Cancer. 2012. PMID: 22666601 Free PMC article. - Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach.
Gann PH, Fought A, Deaton R, Catalona WJ, Vonesh E. Gann PH, et al. J Clin Oncol. 2010 Apr 1;28(10):1714-20. doi: 10.1200/JCO.2008.20.3422. Epub 2010 Feb 22. J Clin Oncol. 2010. PMID: 20177031 Free PMC article. - Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.
Mostaghel EA, Geng L, Holcomb I, Coleman IM, Lucas J, True LD, Nelson PS. Mostaghel EA, et al. Cancer Res. 2010 Feb 15;70(4):1286-95. doi: 10.1158/0008-5472.CAN-09-2509. Epub 2010 Feb 2. Cancer Res. 2010. PMID: 20124490 Free PMC article. - Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer.
Byun YJ, Kang HW, Piao XM, Zheng CM, Moon SK, Choi YH, Kim WT, Lee SC, Yun SJ, Kim WJ. Byun YJ, et al. Prostate Int. 2022 Mar;10(1):1-6. doi: 10.1016/j.prnil.2021.11.003. Epub 2021 Dec 3. Prostate Int. 2022. PMID: 35155300 Free PMC article. - Mediastinal metastasis from ovarian serous carcinoma 29 years after initial treatment.
Inoue E, Yotsumoto T, Inoue Y, Fukami T, Kitani M, Hirano Y, Nagase M, Morio Y. Inoue E, et al. Respir Med Case Rep. 2020 Jan 22;29:101003. doi: 10.1016/j.rmcr.2020.101003. eCollection 2020. Respir Med Case Rep. 2020. PMID: 32257787 Free PMC article.
References
- Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963–968. - PubMed
- Jothy S, Slesak B, Harlozinska A, Lapinska J, Adamiak J, Rabczynski J. Field effect of human colon carcinoma on normal mucosa: Relevance of carcinoembryonic antigen expression. Tumour Biol. 1996;17(1):58–64. - PubMed
- Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, Yoshida O. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res. 1998;58(24):5835–5841. - PubMed
- Rosenthal AN, Ryan A, Hopster D, Jacobs IJ. Molecular evidence of a common clonal origin and subsequent divergent clonal evolution in vulval intraepithelial neoplasia, vulval squamous cell carcinoma and lymph node metastases. Int J Cancer. 2002;99(4):549–554. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical